1. Maintenance therapy with anti-TNF agents has become standard of care in many patients with Crohn's disease since it improves long-term disease
   control, prevents symptom flares and reduces immunogenicity.
    
2. The patient's choice between the two anti-TNF agents infliximab and adalimumab is most often based on published differences in clinical efficacy.
    
3. Elective switching from IFX to ADA is sometimes requested by patients with Crohn's disease to avoid intravenous administration.
    
4. In the "SWITCH" study dose optimisation or interruption of treatment occurred in (47%) in the adalimumab group and in (16%) in the infliximab group
    
5. Elective switching to adalimumab lead to worse outcomes than maintaining treatment with infliximab in the SWITCH study.
    
6. In the SWITCH study intolerance was a more common reason than loss of efficacy for stopping adalimumab
    
7. Elective switching to adalimumab improved outcomes as compared to maintaining treatment with infliximab in the SWITCH study.

please choose... 1,3,4 and 7 are correct 6 and 7 are correct 2,3,4,5 and 6 are correct 2-5 are correct 1,3,4-6 are correct